Zobrazeno 1 - 10
of 261
pro vyhledávání: '"Wei-LI Zhao"'
Autor:
Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Chao Wang, Xin Zheng, Yi-Lun Zhang, Hao-Xu Yang, Wen Wu, Peng-Peng Xu, Shu Cheng, Emmanuel Bachy, Pierre Sesques, Nicolas Jacquet-Francillon, Xu-Feng Jiang, Wei-Li Zhao, Li Wang
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-7 (2024)
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has greatly improved the prognosis of relapsed and refractory patients with large B-cell lymphoma (LBCL). Early identification and intervention of patients who may respond poorly to CAR-T cell
Externí odkaz:
https://doaj.org/article/4b9725d563dd402392bbdf87337f7ad2
Autor:
Zi-Xun Yan, Yan Dong, Niu Qiao, Yi-Lun Zhang, Wen Wu, Yue Zhu, Li Wang, Shu Cheng, Peng-Peng Xu, Zi-Song Zhou, Ling-Shuang Sheng, Wei-Li Zhao
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated promising efficacy in early trials for relapsed/refractory diffuse large B cell lymphoma (DLBCL). However, its efficacy in treating primary refractory DLBCL has not been compr
Externí odkaz:
https://doaj.org/article/85bedf73c3354cb898374211a5705abf
Publikováno v:
Clinical and Translational Discovery, Vol 4, Iss 5, Pp n/a-n/a (2024)
Abstract Background Epstein–Barr virus (EBV) is a double‐stranded DNA herpesvirus and establishes life‐long infection in 95% of the world's populations. Main body EBV is critically involved in multiple diseases. Aberrant signaling pathways, imm
Externí odkaz:
https://doaj.org/article/5511850c7aba4e22aede1185466770b7
Autor:
Ming-Ci Cai, Shu Cheng, Hong-Mei Jing, Yan Liu, Guo-Hui Cui, Ting Niu, Jian-Zhen Shen, Liang Huang, Xin Wang, Yao-Hui Huang, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 50, Iss , Pp 101160- (2024)
Summary: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (c
Externí odkaz:
https://doaj.org/article/7de9b0251dbf4d408a2dc6d1d4a01309
Autor:
Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei-Li Zhao
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Natural killer T cell lymphoma (NKTCL) is highly aggressive, with advanced stage patients poorly responding to intensive chemotherapy. To explore effective and safe treatment for newly diagnosed advanced stage NKTCL, we conducted a phase II
Externí odkaz:
https://doaj.org/article/86ceca8eb03c4db8b1b374d52b9cbacd
Autor:
Zi‐Yang Shi, Ying Fang, Peng‐Peng Xu, Hong‐Mei Yi, Jian‐Feng Li, Yan Dong, Yue Zhu, Meng‐Ke Liu, Di Fu, Shuo Wang, Qing Shi, Rong Shen, Hui‐Juan Zhong, Chao‐Fu Wang, Shu Cheng, Li Wang, Feng Liu, Wei‐Li Zhao
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 6, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/b303849d49b8421d96429c1e748bdafe
Autor:
Ying Fang, Mu-Chen Zhang, Yang He, Chen Li, Hai Fang, Peng-Peng Xu, Shu Cheng, Yan Zhao, Yan Feng, Qian Liu, Li Wang, Wei-Li Zhao
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract TP53 mutation (TP53 mut) occurs in 10–20% of diffuse large B-cell lymphoma (DLBCL) cases and serves as an unfavorable biomarker of DLBCL progression. It confers resistance to immunochemotherapy, high-dose chemotherapy, autologous stem cell
Externí odkaz:
https://doaj.org/article/509a45799370493c818a207e4673b7fa
Autor:
Qing Shi, Yang He, Hong‐Mei Yi, Rong‐Ji Mu, Xu‐Feng Jiang, Di Fu, Lei Dong, Wei Qin, Peng‐Peng Xu, Shu Cheng, Qi Song, Sai‐Juan Chen, Li Wang, Wei‐Li Zhao
Publikováno v:
Cancer Communications, Vol 43, Iss 8, Pp 896-908 (2023)
Abstract Background The current standard of care for non‐bulky diffuse large B‐cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and predni
Externí odkaz:
https://doaj.org/article/1163de2be82f48f9be90c60c27e4f702
Autor:
Pan-pan Zheng, Li-wen Zhang, Dan Sheng, Min-zhen Wang, Rong Li, Wei-li Zhao, Rongmei Liu, Xian Xiu, Yu-sha Zhao, Xi Min, Zhi-kai Wang, Zan-chao Liu
Publikováno v:
Journal of Diabetes Research, Vol 2024 (2024)
Conclusions: Although vitamin E supplementation did not significantly impact HDL levels in individuals with diabetes of any Hp genotype, it may improve HDL function in individuals with Hp2-2 diabetes. These findings indicate a pharmacogenetic interac
Externí odkaz:
https://doaj.org/article/7e8138019fbd40cda46fe8b8f2e0027c
Autor:
Yi‐Ge Shen, Meng‐Meng Ji, Hong‐Mei Yi, Rong Shen, Di Fu, Shu Cheng, Chuan‐Xin Huang, Li Wang, Peng‐Peng Xu, Hong‐Jing Dou, Wei‐Li Zhao
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 1, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/306ace7ada174e4aa9aab49da1fff65f